{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T03:45:18Z","timestamp":1791431118562,"version":"4.3.3"},"publisher-location":"Cham","reference-count":99,"publisher":"Springer International Publishing","isbn-type":[{"value":"9783031237041","type":"print"},{"value":"9783031237058","type":"electronic"}],"license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023]]},"DOI":"10.1007\/978-3-031-23705-8_20","type":"book-chapter","created":{"date-parts":[[2023,7,15]],"date-time":"2023-07-15T08:02:10Z","timestamp":1689408130000},"page":"527-543","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Lymphomas of Central Nervous System"],"prefix":"10.1007","author":[{"given":"Kiyotaka","family":"Yokogami","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minako","family":"Azuma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideo","family":"Takeshima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshinori","family":"Hirai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,7,16]]},"reference":[{"key":"20_CR1","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1200\/JCO.1998.16.3.859","volume":"16","author":"LE Abrey","year":"1998","unstructured":"Abrey LE, DeAngelis LM, Yahalom J (1998) Long-term survival in primary CNS lymphoma. J Clin Oncol 16:859\u2013863. https:\/\/doi.org\/10.1200\/JCO.1998.16.3.859","journal-title":"J Clin Oncol"},{"key":"20_CR2","doi-asserted-by":"publisher","first-page":"5711","DOI":"10.1200\/JCO.2006.08.2941","volume":"24","author":"LE Abrey","year":"2006","unstructured":"Abrey LE et al (2006) Primary central nervous system lymphoma: the memorial Sloan-Kettering cancer center prognostic model. J Clin Oncol 24:5711\u20135715. https:\/\/doi.org\/10.1200\/JCO.2006.08.2941","journal-title":"J Clin Oncol"},{"key":"20_CR3","doi-asserted-by":"publisher","unstructured":"Adachi J et al (2012) O(6)-methylguanine-DNA methyltransferase promoter methylation in 45 primary central nervous system lymphomas: quantitative assessment of methylation and response to temozolomide treatment. J Neurooncol 107:147\u2013153. https:\/\/doi.org\/10.1007\/s11060-011-0721-3","DOI":"10.1007\/s11060-011-0721-3"},{"key":"20_CR4","doi-asserted-by":"publisher","first-page":"1564","DOI":"10.3174\/ajnr.A2035","volume":"31","author":"AK Bag","year":"2010","unstructured":"Bag AK, Cure JK, Chapman PR, Roberson GH, Shah R (2010) JC virus infection of the brain. AJNR Am J Neuroradiol 31:1564\u20131576. https:\/\/doi.org\/10.3174\/ajnr.A2035","journal-title":"AJNR Am J Neuroradiol"},{"key":"20_CR5","doi-asserted-by":"publisher","unstructured":"Basso K, Dalla-Favera R (2012) Roles of BCL6 in normal and transformed germinal center B cells. Immunol Rev 247:172\u2013183. https:\/\/doi.org\/10.1111\/j.1600-065X.2012.01112.x","DOI":"10.1111\/j.1600-065X.2012.01112.x"},{"key":"20_CR6","doi-asserted-by":"publisher","unstructured":"Bataille B et al (2000) Primary intracerebral malignant lymphoma: report of 248 cases. J Neurosurg 92:261\u2013266. https:\/\/doi.org\/10.3171\/jns.2000.92.2.0261","DOI":"10.3171\/jns.2000.92.2.0261"},{"key":"20_CR7","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1200\/JCO.2005.04.8819","volume":"24","author":"T Batchelor","year":"2006","unstructured":"Batchelor T, Loeffler JS (2006) Primary CNS lymphoma. J Clin Oncol 24:1281\u20131288. https:\/\/doi.org\/10.1200\/JCO.2005.04.8819","journal-title":"J Clin Oncol"},{"key":"20_CR8","first-page":"1063","volume":"9","author":"KM Braaten","year":"2003","unstructured":"Braaten KM et al (2003) BCL-6 expression predicts improved survival in patients with primary central nervous system lymphoma. Clin Cancer Res 9:1063\u20131069","journal-title":"Clin Cancer Res"},{"key":"20_CR9","doi-asserted-by":"publisher","unstructured":"Braggio E et al (2011) Primary central nervous system lymphomas: a validation study of array-based comparative genomic hybridization in formalin-fixed paraffin-embedded tumor specimens. Clin Cancer Res 17:4245\u20134253. https:\/\/doi.org\/10.1158\/1078-0432.CCR-11-0395. 1078-0432.CCR-11-0395 [pii]","DOI":"10.1158\/1078-0432.CCR-11-0395"},{"key":"20_CR10","doi-asserted-by":"publisher","unstructured":"Braggio E et al (2015) Genome-wide analysis uncovers novel recurrent alterations in primary central nervous system lymphomas. Clin Cancer Res 21:3986\u20133994. https:\/\/doi.org\/10.1158\/1078-0432.CCR-14-2116. 1078-0432.CCR-14-2116 [pii]","DOI":"10.1158\/1078-0432.CCR-14-2116"},{"key":"20_CR11","doi-asserted-by":"publisher","unstructured":"Brain Tumor Registry of Japan (2005\u20132008) (2017) Neurol Med Chir (Tokyo) 57:9\u2013102. https:\/\/doi.org\/10.2176\/nmc.sup.2017-0001","DOI":"10.2176\/nmc.sup.2017-0001"},{"key":"20_CR12","doi-asserted-by":"publisher","unstructured":"Bruno A et al (2014) Mutational analysis of primary central nervous system lymphoma. Oncotarget 5:5065\u20135075. 2080 [pii]. https:\/\/doi.org\/10.18632\/oncotarget.2080","DOI":"10.18632\/oncotarget.2080"},{"key":"20_CR13","doi-asserted-by":"publisher","unstructured":"Cai Q, Fang Y, Young KH (2019) Primary central nervous system lymphoma: molecular pathogenesis and advances in treatment. Transl Oncol 12:523\u2013538. S1936-5233(18)30594-1 [pii]. https:\/\/doi.org\/10.1016\/j.tranon.2018.11.011","DOI":"10.1016\/j.tranon.2018.11.011"},{"key":"20_CR14","doi-asserted-by":"publisher","unstructured":"Camilleri-Broet S et al (2006) A uniform activated B-cell-like immunophenotype might explain the poor prognosis of primary central nervous system lymphomas: analysis of 83 cases. Blood 107:190\u2013196. 2005-03-1024 [pii]. https:\/\/doi.org\/10.1182\/blood-2005-03-1024","DOI":"10.1182\/blood-2005-03-1024"},{"key":"20_CR15","doi-asserted-by":"publisher","first-page":"E6","DOI":"10.3171\/foc.2006.21.5.7","volume":"21","author":"MC Chamberlain","year":"2006","unstructured":"Chamberlain MC (2006) Lymphomatous meningitis in primary central nervous system lymphoma. Neurosurg Focus 21:E6. https:\/\/doi.org\/10.3171\/foc.2006.21.5.7","journal-title":"Neurosurg Focus"},{"key":"20_CR16","doi-asserted-by":"publisher","first-page":"1589","DOI":"10.1634\/theoncologist.2011-0210","volume":"16","author":"CC Chan","year":"2011","unstructured":"Chan CC et al (2011) Primary vitreoretinal lymphoma: a report from an international primary central nervous system lymphoma collaborative group symposium. Oncologist 16:1589\u20131599. https:\/\/doi.org\/10.1634\/theoncologist.2011-0210","journal-title":"Oncologist"},{"key":"20_CR17","doi-asserted-by":"publisher","unstructured":"Chapuy B et al (2016) Targetable genetic features of primary testicular and primary central nervous system lymphomas. Blood 127:869\u2013881. https:\/\/doi.org\/10.1182\/blood-2015-10-673236. blood-2015-10-673236 [pii]","DOI":"10.1182\/blood-2015-10-673236"},{"key":"20_CR18","doi-asserted-by":"publisher","first-page":"2487","DOI":"10.1002\/ijc.22124","volume":"119","author":"LC Chu","year":"2006","unstructured":"Chu LC, Eberhart CG, Grossman SA, Herman JG (2006) Epigenetic silencing of multiple genes in primary CNS lymphoma. Int J Cancer 119:2487\u20132491. https:\/\/doi.org\/10.1002\/ijc.22124","journal-title":"Int J Cancer"},{"key":"20_CR19","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1016\/s0360-3016(97)00571-3","volume":"41","author":"J Corry","year":"1998","unstructured":"Corry J, Smith JG, Wirth A, Quong G, Liew KH (1998) Primary central nervous system lymphoma: age and performance status are more important than treatment modality. Int J Radiat Oncol Biol Phys 41:615\u2013620. https:\/\/doi.org\/10.1016\/s0360-3016(97)00571-3","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"20_CR20","doi-asserted-by":"publisher","unstructured":"Coulon A, Lafitte F, Hoang-Xuan K, Martin-Duverneuil N, Mokhtari K, Blustajn J, Chiras J (2002) Radiographic findings in 37 cases of primary CNS lymphoma in immunocompetent patients. Eur Radiol 12:329\u2013340. https:\/\/doi.org\/10.1007\/s003300101037","DOI":"10.1007\/s003300101037"},{"key":"20_CR21","doi-asserted-by":"publisher","unstructured":"Courts C et al (2007) Transcriptional profiling of the nuclear factor-kappa B pathway identifies a subgroup of primary lymphoma of the central nervous system with low BCL10 expression. J Neuropathol Exp Neurol 66:230\u2013237. https:\/\/doi.org\/10.1097\/01.jnen.0000248553.45456.96. 00005072-200703000-00007 [pii]","DOI":"10.1097\/01.jnen.0000248553.45456.96"},{"key":"20_CR22","doi-asserted-by":"publisher","unstructured":"DeAngelis LM, Seiferheld W, Schold SC, Fisher B, Schultz CJ (2002) Combination chemotherapy and radiotherapy for primary central nervous system lymphoma: radiation therapy oncology group study 93\u201310. J Clin Oncol 20:4643\u20134648. https:\/\/doi.org\/10.1200\/JCO.2002.11.013","DOI":"10.1200\/JCO.2002.11.013"},{"key":"20_CR23","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1007\/s00401-013-1202-x","volume":"127","author":"M Deckert","year":"2014","unstructured":"Deckert M, Montesinos-Rongen M, Brunn A, Siebert R (2014) Systems biology of primary CNS lymphoma: from genetic aberrations to modeling in mice. Acta Neuropathol 127:175\u2013188. https:\/\/doi.org\/10.1007\/s00401-013-1202-x","journal-title":"Acta Neuropathol"},{"key":"20_CR24","doi-asserted-by":"publisher","unstructured":"Doolittle ND et al (2013) Long-term cognitive function, neuroimaging, and quality of life in primary CNS lymphoma. Neurology 81:84\u201392. https:\/\/doi.org\/10.1212\/WNL.0b013e318297eeba. WNL.0b013e318297eeba [pii]","DOI":"10.1212\/WNL.0b013e318297eeba"},{"key":"20_CR25","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1200\/JCO.2003.09.139","volume":"21","author":"AJ Ferreri","year":"2003","unstructured":"Ferreri AJ et al (2003) Prognostic scoring system for primary CNS lymphomas: the international extranodal lymphoma study group experience. J Clin Oncol 21:266\u2013272. https:\/\/doi.org\/10.1200\/JCO.2003.09.139","journal-title":"J Clin Oncol"},{"key":"20_CR26","doi-asserted-by":"publisher","unstructured":"Ferreri AJ et al (2004) Aberrant methylation in the promoter region of the reduced folate carrier gene is a potential mechanism of resistance to methotrexate in primary central nervous system lymphomas. Br J Haematol 126:657\u2013664. https:\/\/doi.org\/10.1111\/j.1365-2141.2004.05109.x. BJH5109 [pii]","DOI":"10.1111\/j.1365-2141.2004.05109.x"},{"key":"20_CR27","doi-asserted-by":"publisher","unstructured":"Ferreri AJ, Verona C, Politi LS, Chiara A, Perna L, Villa E, Reni M (2011) Consolidation radiotherapy in primary central nervous system lymphomas: impact on outcome of different fields and doses in patients in complete remission after upfront chemotherapy. Int J Radiat Oncol Biol Phys 80:169\u2013175. https:\/\/doi.org\/10.1016\/j.ijrobp.2010.01.066. S0360-3016(10)00269-5 [pii]","DOI":"10.1016\/j.ijrobp.2010.01.066"},{"key":"20_CR28","doi-asserted-by":"publisher","unstructured":"Ferreri AJ et al (2009) High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: a randomised phase 2 trial. Lancet 374:1512\u20131520. https:\/\/doi.org\/10.1016\/S0140-6736(09)61416-1. S0140-6736(09)61416-1 [pii]","DOI":"10.1016\/S0140-6736(09)61416-1"},{"key":"20_CR29","doi-asserted-by":"publisher","unstructured":"Ferreri AJ et al (2016) Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the international extranodal lymphoma study group-32 (IELSG32) phase 2 trial. Lancet Haematol 3:e217\u2013227. https:\/\/doi.org\/10.1016\/S2352-3026(16)00036-3. S2352-3026(16)00036-3 [pii]","DOI":"10.1016\/S2352-3026(16)00036-3"},{"key":"20_CR30","doi-asserted-by":"publisher","unstructured":"Ferreri AJM et al (2017) Whole-brain radiotherapy or autologous stem-cell transplantation as consolidation strategies after high-dose methotrexate-based chemoimmunotherapy in patients with primary CNS lymphoma: results of the second randomisation of the international extranodal lymphoma study group-32 phase 2 trial. Lancet Haematol 4:e510\u2013e523. S2352-3026(17)30174-6 [pii]. https:\/\/doi.org\/10.1016\/S2352-3026(17)30174-6","DOI":"10.1016\/S2352-3026(17)30174-6"},{"key":"20_CR31","doi-asserted-by":"publisher","unstructured":"Fischer L, Hummel M, Korfel A, Lenze D, Joehrens K, Thiel E (2011) Differential micro-RNA expression in primary CNS and nodal diffuse large B-cell lymphomas. Neuro Oncol 13:1090\u20131098. https:\/\/doi.org\/10.1093\/neuonc\/nor107.nor107 [pii]","DOI":"10.1093\/neuonc\/nor107.nor107"},{"key":"20_CR32","doi-asserted-by":"publisher","unstructured":"Glass J et al (2016) Phase I and II study of induction chemotherapy with methotrexate, rituximab, and temozolomide, followed by whole-brain radiotherapy and postirradiation temozolomide for primary CNS lymphoma: NRG oncology RTOG 0227. J Clin Oncol 34:1620\u20131625. https:\/\/doi.org\/10.1200\/JCO.2015.64.8634. JCO.2015.64.8634 [pii]","DOI":"10.1200\/JCO.2015.64.8634"},{"key":"20_CR33","doi-asserted-by":"publisher","first-page":"E4","DOI":"10.3171\/foc.2006.21.5.5","volume":"21","author":"JL Go","year":"2006","unstructured":"Go JL, Lee SC, Kim PE (2006) Imaging of primary central nervous system lymphoma. Neurosurg Focus 21:E4. https:\/\/doi.org\/10.3171\/foc.2006.21.5.5","journal-title":"Neurosurg Focus"},{"key":"20_CR34","doi-asserted-by":"publisher","unstructured":"Gonzalez-Aguilar A et al (2012) Recurrent mutations of MYD88 and TBL1XR1 in primary central nervous system lymphomas. Clin Cancer Res 18:5203\u20135211. https:\/\/doi.org\/10.1158\/1078-0432.CCR-12-0845. 1078-0432.CCR-12-0845 [pii]","DOI":"10.1158\/1078-0432.CCR-12-0845"},{"key":"20_CR35","doi-asserted-by":"publisher","unstructured":"Gonzalez-Gomez P et al (2003) CpG island methylation of tumor-related genes in three primary central nervous system lymphomas in immunocompetent patients. Cancer Genet Cytogenet 142:21\u201324. S0165460802007999 [pii]. https:\/\/doi.org\/10.1016\/s0165-4608(02)00799-9","DOI":"10.1016\/s0165-4608(02)00799-9"},{"key":"20_CR36","doi-asserted-by":"publisher","first-page":"2410","DOI":"10.1200\/JCO.2017.72.7602","volume":"35","author":"C Grommes","year":"2017","unstructured":"Grommes C, DeAngelis LM (2017) Primary CNS lymphoma. J Clin Oncol 35:2410\u20132418. https:\/\/doi.org\/10.1200\/JCO.2017.72.7602","journal-title":"J Clin Oncol"},{"key":"20_CR37","doi-asserted-by":"publisher","first-page":"984","DOI":"10.3174\/ajnr.A2171","volume":"32","author":"IS Haldorsen","year":"2011","unstructured":"Haldorsen IS, Espeland A, Larsson EM (2011) Central nervous system lymphoma: characteristic findings on traditional and advanced imaging. AJNR Am J Neuroradiol 32:984\u2013992. https:\/\/doi.org\/10.3174\/ajnr.A2171","journal-title":"AJNR Am J Neuroradiol"},{"key":"20_CR38","doi-asserted-by":"publisher","unstructured":"Haldorsen IS, Krakenes J, Goplen AK, Dunlop O, Mella O, Espeland A (2008) AIDS-related primary central nervous system lymphoma: a Norwegian national survey 1989\u20132003. BMC Cancer 8:225. https:\/\/doi.org\/10.1186\/1471-2407-8-225","DOI":"10.1186\/1471-2407-8-225"},{"key":"20_CR39","doi-asserted-by":"publisher","unstructured":"Haldorsen IS, Krakenes J, Krossnes BK, Mella O, Espeland A (2009) CT and MR imaging features of primary central nervous system lymphoma in Norway, 1989\u20132003. AJNR Am J Neuroradiol 30:744\u2013751. https:\/\/doi.org\/10.3174\/ajnr.A1447","DOI":"10.3174\/ajnr.A1447"},{"key":"20_CR40","doi-asserted-by":"publisher","first-page":"4314","DOI":"10.1002\/cncr.30965","volume":"123","author":"CH Han","year":"2017","unstructured":"Han CH, Batchelor TT (2017) Diagnosis and management of primary central nervous system lymphoma. Cancer 123:4314\u20134324. https:\/\/doi.org\/10.1002\/cncr.30965","journal-title":"Cancer"},{"key":"20_CR41","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/s0304-3940(02)01367-8","volume":"338","author":"M Hartmann","year":"2003","unstructured":"Hartmann M, Heiland S, Harting I, Tronnier VM, Sommer C, Ludwig R, Sartor K (2003) Distinguishing of primary cerebral lymphoma from high-grade glioma with perfusion-weighted magnetic resonance imaging. Neurosci Lett 338:119\u2013122. https:\/\/doi.org\/10.1016\/s0304-3940(02)01367-8","journal-title":"Neurosci Lett"},{"key":"20_CR42","doi-asserted-by":"publisher","unstructured":"Herrlinger U et al (2017) Early whole brain radiotherapy in primary CNS lymphoma: negative impact on quality of life in the randomized G-PCNSL-SG1 trial. J Cancer Res Clin Oncol 143:1815\u20131821. https:\/\/doi.org\/10.1007\/s00432-017-2423-5. [pii]","DOI":"10.1007\/s00432-017-2423-5"},{"key":"20_CR43","doi-asserted-by":"publisher","unstructured":"Hoang-Xuan K et al (2015) Diagnosis and treatment of primary CNS lymphoma in immunocompetent patients: guidelines from the European association for neuro-oncology. Lancet Oncol 16:e322\u2013332. https:\/\/doi.org\/10.1016\/S1470-2045(15)00076-5. S1470-2045(15)00076-5 [pii]","DOI":"10.1016\/S1470-2045(15)00076-5"},{"key":"20_CR44","doi-asserted-by":"publisher","unstructured":"Hoang-Xuan K et al (2003) Chemotherapy alone as initial treatment for primary CNS lymphoma in patients older than 60 years: a multicenter phase II study (26952) of the European organization for research and treatment of cancer brain tumor group. J Clin Oncol 21:2726\u20132731. https:\/\/doi.org\/10.1200\/JCO.2003.11.036. JCO.2003.11.036 [pii]","DOI":"10.1200\/JCO.2003.11.036"},{"key":"20_CR45","doi-asserted-by":"publisher","unstructured":"Illerhaus G et al (2016) High-dose chemotherapy with autologous haemopoietic stem cell transplantation for newly diagnosed primary CNS lymphoma: a prospective, single-arm, phase 2 trial. Lancet Haematol 3:e388\u2013397. https:\/\/doi.org\/10.1016\/S2352-3026(16)30050-3. S2352-3026(16)30050-3 [pii]","DOI":"10.1016\/S2352-3026(16)30050-3"},{"key":"20_CR46","doi-asserted-by":"publisher","unstructured":"Jahnke K et al (2005) High-dose methotrexate toxicity in elderly patients with primary central nervous system lymphoma Ann Oncol 16:445\u2013449. S0923-7534(19)47863-0 [pii]. https:\/\/doi.org\/10.1093\/annonc\/mdi075","DOI":"10.1093\/annonc\/mdi075"},{"key":"20_CR47","doi-asserted-by":"publisher","unstructured":"Jahnke K, Thiel E, Martus P, Herrlinger U, Weller M, Fischer L, Korfel A (2006) Relapse of primary central nervous system lymphoma: clinical features, outcome and prognostic factors. J Neurooncol 80:159\u2013165. https:\/\/doi.org\/10.1007\/s11060-006-9165-6","DOI":"10.1007\/s11060-006-9165-6"},{"key":"20_CR48","doi-asserted-by":"publisher","unstructured":"Kasenda B et al (2013) 18F-FDG PET is an independent outcome predictor in primary central nervous system lymphoma. J Nucl Med 54:184\u2013191. https:\/\/doi.org\/10.2967\/jnumed.112.108654","DOI":"10.2967\/jnumed.112.108654"},{"key":"20_CR49","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1038\/nrneurol.2013.83","volume":"9","author":"A Korfel","year":"2013","unstructured":"Korfel A, Schlegel U (2013) Diagnosis and treatment of primary CNS lymphoma. Nat Rev Neurol 9:317\u2013327. https:\/\/doi.org\/10.1038\/nrneurol.2013.83","journal-title":"Nat Rev Neurol"},{"key":"20_CR50","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1007\/s00330-004-2626-4","volume":"15","author":"G Krumina","year":"2005","unstructured":"Krumina G (2005) Metastatic disease of the brain: parenchyma. Eur Radiol 15:608\u2013616. https:\/\/doi.org\/10.1007\/s00330-004-2626-4","journal-title":"Eur Radiol"},{"key":"20_CR51","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1007\/s11060-009-0032-0","volume":"97","author":"D Kurzwelly","year":"2010","unstructured":"Kurzwelly D et al (2010) Primary CNS lymphoma in the elderly: temozolomide therapy and MGMT status. J Neurooncol 97:389\u2013392. https:\/\/doi.org\/10.1007\/s11060-009-0032-0","journal-title":"J Neurooncol"},{"key":"20_CR52","doi-asserted-by":"publisher","first-page":"1557","DOI":"10.1212\/01.wnl.0000034256.20173.ea","volume":"59","author":"R Lai","year":"2002","unstructured":"Lai R, Rosenblum MK, DeAngelis LM (2002) Primary CNS lymphoma: a whole-brain disease? Neurology 59:1557\u20131562. https:\/\/doi.org\/10.1212\/01.wnl.0000034256.20173.ea","journal-title":"Neurology"},{"key":"20_CR53","doi-asserted-by":"publisher","unstructured":"Langner-Lemercier S et al (2016) Primary CNS lymphoma at first relapse\/progression: characteristics, management, and outcome of 256 patients from the French LOC network. Neuro Oncol 18:1297\u20131303. https:\/\/doi.org\/10.1093\/neuonc\/now033. now033 [pii]","DOI":"10.1093\/neuonc\/now033"},{"key":"20_CR54","doi-asserted-by":"publisher","unstructured":"Levy O, Deangelis LM, Filippa DA, Panageas KS, Abrey LE (2008) Bcl-6 predicts improved prognosis in primary central nervous system lymphoma. Cancer 112:151\u2013156. https:\/\/doi.org\/10.1002\/cncr.23149","DOI":"10.1002\/cncr.23149"},{"key":"20_CR55","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1007\/s12149-011-0506-y","volume":"25","author":"Y Liu","year":"2011","unstructured":"Liu Y (2011) Demonstrations of AIDS-associated malignancies and infections at FDG PET-CT. Ann Nucl Med 25:536\u2013546. https:\/\/doi.org\/10.1007\/s12149-011-0506-y","journal-title":"Ann Nucl Med"},{"key":"20_CR56","doi-asserted-by":"publisher","unstructured":"Louis DN et al (2016) The 2016 world health organization classification of tumors of the central nervous system: a summary. Acta Neuropathol 131:803\u2013820. https:\/\/doi.org\/10.1007\/s00401-016-1545-1. [pii]","DOI":"10.1007\/s00401-016-1545-1"},{"key":"20_CR57","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1002\/cncr.21583","volume":"106","author":"BS Mathew","year":"2006","unstructured":"Mathew BS, Carson KA, Grossman SA (2006) Initial response to glucocorticoids. Cancer 106:383\u2013387. https:\/\/doi.org\/10.1002\/cncr.21583","journal-title":"Cancer"},{"key":"20_CR58","doi-asserted-by":"publisher","unstructured":"Mendez JS, Ostrom QT, Gittleman H, Kruchko C, DeAngelis LM, Barnholtz-Sloan JS, Grommes C (2018) The elderly left behind-changes in survival trends of primary central nervous system lymphoma over the past 4 decades. Neuro Oncol 20:687\u2013694 https:\/\/doi.org\/10.1093\/neuonc\/nox187","DOI":"10.1093\/neuonc\/nox187"},{"key":"20_CR59","doi-asserted-by":"publisher","unstructured":"Mittal S, Wu Z, Neelavalli J, Haacke EM (2009) Susceptibility-weighted imaging: technical aspects and clinical applications, part 2. AJNR Am J Neuroradiol 30:232\u2013252. https:\/\/doi.org\/10.3174\/ajnr.A1461","DOI":"10.3174\/ajnr.A1461"},{"key":"20_CR60","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1093\/jnen\/61.10.926","volume":"61","author":"M Montesinos-Rongen","year":"2002","unstructured":"Montesinos-Rongen M et al (2002) Interphase cytogenetic analysis of lymphoma-associated chromosomal breakpoints in primary diffuse large B-cell lymphomas of the central nervous system. J Neuropathol Exp Neurol 61:926\u2013933. https:\/\/doi.org\/10.1093\/jnen\/61.10.926","journal-title":"J Neuropathol Exp Neurol"},{"key":"20_CR61","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1007\/s00401-012-1064-7","volume":"124","author":"M Montesinos-Rongen","year":"2012","unstructured":"Montesinos-Rongen M, Schafer E, Siebert R, Deckert M (2012) Genes regulating the B cell receptor pathway are recurrently mutated in primary central nervous system lymphoma. Acta Neuropathol 124:905\u2013906. https:\/\/doi.org\/10.1007\/s00401-012-1064-7","journal-title":"Acta Neuropathol"},{"key":"20_CR62","doi-asserted-by":"publisher","unstructured":"Montesinos-Rongen M, Van Roost D, Schaller C, Wiestler OD, Deckert M (2004) Primary diffuse large B-cell lymphomas of the central nervous system are targeted by aberrant somatic hypermutation. Blood 103:1869\u20131875. https:\/\/doi.org\/10.1182\/blood-2003-05-1465. 2003-05-1465 [pii]","DOI":"10.1182\/blood-2003-05-1465"},{"key":"20_CR63","doi-asserted-by":"publisher","unstructured":"Montesinos-Rongen M et al (2008) Gene expression profiling suggests primary central nervous system lymphomas to be derived from a late germinal center B cell. Leukemia 22:400\u2013405. 2405019 [pii]. https:\/\/doi.org\/10.1038\/sj.leu.2405019","DOI":"10.1038\/sj.leu.2405019"},{"key":"20_CR64","doi-asserted-by":"publisher","unstructured":"Montesinos-Rongen M, Siebert R, Deckert M (2009) Primary lymphoma of the central nervous system: just DLBCL or not? Blood 113:7\u201310. https:\/\/doi.org\/10.1182\/blood-2008-04-149005. blood-2008-04-149005 [pii]","DOI":"10.1182\/blood-2008-04-149005"},{"key":"20_CR65","doi-asserted-by":"publisher","unstructured":"Montesinos-Rongen M et al (1999) Primary central nervous system lymphomas are derived from germinal-center B cells and show a preferential usage of the V4\u201334 gene segment. Am J Pathol 155:2077\u20132086. https:\/\/doi.org\/10.1016\/S0002-9440(10)65526-5","DOI":"10.1016\/S0002-9440(10)65526-5"},{"key":"20_CR66","doi-asserted-by":"publisher","unstructured":"Morris PG et al (2013) Rituximab, methotrexate, procarbazine, and vincristine followed by consolidation reduced-dose whole-brain radiotherapy and cytarabine in newly diagnosed primary CNS lymphoma: final results and long-term outcome. J Clin Oncol 31:3971\u20133979. https:\/\/doi.org\/10.1200\/JCO.2013.50.4910. JCO.2013.50.4910 [pii]","DOI":"10.1200\/JCO.2013.50.4910"},{"key":"20_CR67","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1007\/s11912-009-0012-8","volume":"11","author":"MM Mrugala","year":"2009","unstructured":"Mrugala MM, Rubenstein JL, Ponzoni M, Batchelor TT (2009) Insights into the biology of primary central nervous system lymphoma. Curr Oncol Rep 11:73\u201380. https:\/\/doi.org\/10.1007\/s11912-009-0012-8","journal-title":"Curr Oncol Rep"},{"key":"20_CR68","doi-asserted-by":"publisher","unstructured":"Nakamura T et al (2016) Recurrent mutations of CD79B and MYD88 are the hallmark of primary central nervous system lymphomas. Neuropathol Appl Neurobiol 42:279\u2013290. https:\/\/doi.org\/10.1111\/nan.12259","DOI":"10.1111\/nan.12259"},{"key":"20_CR69","doi-asserted-by":"publisher","unstructured":"Nelson DF et al (1992) Non-Hodgkin\u2019s lymphoma of the brain: can high dose, large volume radiation therapy improve survival? Report on a prospective trial by the radiation therapy oncology group (RTOG): RTOG 8315. Int J Radiat Oncol Biol Phys 23:9\u201317. https:\/\/doi.org\/10.1016\/0360-3016(92)90538-s","DOI":"10.1016\/0360-3016(92)90538-s"},{"key":"20_CR70","doi-asserted-by":"publisher","unstructured":"Ngo VN et al (2011) Oncogenically active MYD88 mutations in human lymphoma. Nature 470:115\u2013119. https:\/\/doi.org\/10.1038\/nature09671. nature09671 [pii]","DOI":"10.1038\/nature09671"},{"key":"20_CR71","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1148\/radiographics.14.1.8128041","volume":"14","author":"T Ogawa","year":"1994","unstructured":"Ogawa T et al (1994) Methionine PET for follow-up of radiation therapy of primary lymphoma of the brain. Radiographics 14:101\u2013110. https:\/\/doi.org\/10.1148\/radiographics.14.1.8128041","journal-title":"Radiographics"},{"key":"20_CR72","doi-asserted-by":"publisher","unstructured":"Omuro A et al (2015) R-MPV followed by high-dose chemotherapy with TBC and autologous stem-cell transplant for newly diagnosed primary CNS lymphoma. Blood 125:1403\u20131410. https:\/\/doi.org\/10.1182\/blood-2014-10-604561. blood-2014-10-604561 [pii]","DOI":"10.1182\/blood-2014-10-604561"},{"key":"20_CR73","doi-asserted-by":"publisher","first-page":"1356","DOI":"10.1016\/0277-5379(91)90009-3","volume":"27","author":"RJ Ott","year":"1991","unstructured":"Ott RJ, Brada M, Flower MA, Babich JW, Cherry SR, Deehan BJ (1991) Measurements of blood-brain barrier permeability in patients undergoing radiotherapy and chemotherapy for primary cerebral lymphoma. Eur J Cancer 27:1356\u20131361. https:\/\/doi.org\/10.1016\/0277-5379(91)90009-3","journal-title":"Eur J Cancer"},{"key":"20_CR74","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.jns.2004.11.038","volume":"228","author":"H Pels","year":"2005","unstructured":"Pels H, Montesinos-Rongen M, Schaller C, Schlegel U, Schmidt-Wolf IG, Wiestler OD, Deckert M (2005) VH gene analysis of primary CNS lymphomas. J Neurol Sci 228:143\u2013147. https:\/\/doi.org\/10.1016\/j.jns.2004.11.038","journal-title":"J Neurol Sci"},{"key":"20_CR75","doi-asserted-by":"publisher","unstructured":"Peters S, Knoss N, Wodarg F, Cnyrim C, Jansen O (2012) Glioblastomas vs. lymphomas: more diagnostic certainty by using susceptibility-weighted imaging (SWI). Rofo 184:713\u2013718. https:\/\/doi.org\/10.1055\/s-0032-1312862","DOI":"10.1055\/s-0032-1312862"},{"key":"20_CR76","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1023\/a:1005733416571","volume":"32","author":"B Pirotte","year":"1997","unstructured":"Pirotte B, Levivier M, Goldman S, Brucher JM, Brotchi J, Hildebrand J (1997) Glucocorticoid-induced long-term remission in primary cerebral lymphoma: case report and review of the literature. J Neurooncol 32:63\u201369. https:\/\/doi.org\/10.1023\/a:1005733416571","journal-title":"J Neurooncol"},{"key":"20_CR77","doi-asserted-by":"publisher","unstructured":"Rickert CH, Dockhorn-Dworniczak B, Simon R, Paulus W (1999) Chromosomal imbalances in primary lymphomas of the central nervous system. Am J Pathol 155:1445\u20131451. S0002-9440(10)65458-2 [pii]. https:\/\/doi.org\/10.1016\/S0002-9440(10)65458-2","DOI":"10.1016\/S0002-9440(10)65458-2"},{"key":"20_CR78","doi-asserted-by":"publisher","unstructured":"Rimsza LM et al (2004) Loss of MHC class II gene and protein expression in diffuse large B-cell lymphoma is related to decreased tumor immunosurveillance and poor patient survival regardless of other prognostic factors: a follow-up study from the leukemia and lymphoma molecular profiling project. Blood 103:4251\u20134258. https:\/\/doi.org\/10.1182\/blood-2003-07-2365. 2003-07-2365 [pii]","DOI":"10.1182\/blood-2003-07-2365"},{"key":"20_CR79","doi-asserted-by":"publisher","unstructured":"Robertus JL et al (2009) Specific expression of miR-17-5p and miR-127 in testicular and central nervous system diffuse large B-cell lymphoma. Mod Pathol 22:547\u2013555. https:\/\/doi.org\/10.1038\/modpathol.2009.10. modpathol200910 [pii]","DOI":"10.1038\/modpathol.2009.10"},{"key":"20_CR80","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1097\/WCO.0000000000000492","volume":"30","author":"L Royer-Perron","year":"2017","unstructured":"Royer-Perron L, Hoang-Xuan K, Alentorn A (2017) Primary central nervous system lymphoma: time for diagnostic biomarkers and biotherapies? Curr Opin Neurol 30:669\u2013676. https:\/\/doi.org\/10.1097\/WCO.0000000000000492","journal-title":"Curr Opin Neurol"},{"key":"20_CR81","doi-asserted-by":"publisher","unstructured":"Rubenstein JL, Treseler P, O\u2019Brien JM (2005) Pathology and genetics of primary central nervous system and intraocular lymphoma. Hematol Oncol Clin North Am 19:705\u2013717, vii. S0889-8588(05)00046-8 [pii]. https:\/\/doi.org\/10.1016\/j.hoc.2005.05.012","DOI":"10.1016\/j.hoc.2005.05.012"},{"key":"20_CR82","doi-asserted-by":"publisher","unstructured":"Rubenstein JL et al (2013) Intensive chemotherapy and immunotherapy in patients with newly diagnosed primary CNS lymphoma: CALGB 50202 (Alliance 50202). J Clin Oncol 31:3061\u20133068. https:\/\/doi.org\/10.1200\/JCO.2012.46.9957. JCO.2012.46.9957 [pii]","DOI":"10.1200\/JCO.2012.46.9957"},{"key":"20_CR83","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1515\/raon-2015-0007","volume":"49","author":"A Sakata","year":"2015","unstructured":"Sakata A et al (2015) Primary central nervous system lymphoma: is absence of intratumoral hemorrhage a characteristic finding on MRI? Radiol Oncol 49:128\u2013134. https:\/\/doi.org\/10.1515\/raon-2015-0007","journal-title":"Radiol Oncol"},{"key":"20_CR84","doi-asserted-by":"publisher","unstructured":"Schlegel U, Schmidt-Wolf IG, Deckert M (2000) Primary CNS lymphoma: clinical presentation, pathological classification, molecular pathogenesis and treatment. J Neurol Sci 181:1\u201312. https:\/\/doi.org\/10.1016\/s0022-510x(00)00385-3","DOI":"10.1016\/s0022-510x(00)00385-3"},{"key":"20_CR85","doi-asserted-by":"publisher","unstructured":"Schultz C et al (1996) Preirradiation chemotherapy with cyclophosphamide, doxorubicin, vincristine, and dexamethasone for primary CNS lymphomas: initial report of radiation therapy oncology group protocol 88\u201306. J Clin Oncol 14:556\u2013564. https:\/\/doi.org\/10.1200\/JCO.1996.14.2.556","DOI":"10.1200\/JCO.1996.14.2.556"},{"key":"20_CR86","doi-asserted-by":"publisher","unstructured":"Schwindt H et al (2009) Chromosomal imbalances and partial uniparental disomies in primary central nervous system lymphoma. Leukemia 23:1875\u20131884. https:\/\/doi.org\/10.1038\/leu.2009.120. leu2009120 [pii]","DOI":"10.1038\/leu.2009.120"},{"key":"20_CR87","doi-asserted-by":"publisher","unstructured":"Shiels MS et al (2016) Trends in primary central nervous system lymphoma incidence and survival in the US. Br J Haematol 174:417\u2013424. https:\/\/doi.org\/10.1111\/bjh.14073","DOI":"10.1111\/bjh.14073"},{"key":"20_CR88","unstructured":"The Japan society for Neuro-oncology groups (2019) Practical guidelines for neuro-oncology 2019 from Kanehara & CO., LTD. WWW document. https:\/\/www.jsn-o.com\/guideline3\/CQ\/general3.html"},{"key":"20_CR89","doi-asserted-by":"publisher","unstructured":"Thiel E et al (2010) High-dose methotrexate with or without whole brain radiotherapy for primary CNS lymphoma (G-PCNSL-SG-1): a phase 3, randomised, non-inferiority trial. Lancet Oncol 11:1036\u20131047. https:\/\/doi.org\/10.1016\/S1470-2045(10)70229-1. S1470-2045(10)70229-1 [pii]","DOI":"10.1016\/S1470-2045(10)70229-1"},{"key":"20_CR90","doi-asserted-by":"crossref","unstructured":"Thompsett AR, Ellison DW, Stevenson FK, Zhu D (1999) V(H) gene sequences from primary central nervous system lymphomas indicate derivation from highly mutated germinal center B cells with ongoing mutational activity. Blood 94:1738\u20131746","DOI":"10.1182\/blood.V94.5.1738"},{"key":"20_CR91","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1007\/s002340000480","volume":"43","author":"MM Thurnher","year":"2001","unstructured":"Thurnher MM, Rieger A, Kleibl-Popov C, Settinek U, Henk C, Haberler C, Schindler E (2001) Primary central nervous system lymphoma in AIDS: a wider spectrum of CT and MRI findings. Neuroradiology 43:29\u201335. https:\/\/doi.org\/10.1007\/s002340000480","journal-title":"Neuroradiology"},{"key":"20_CR92","doi-asserted-by":"publisher","unstructured":"Todorovic Balint M et al (2016) Gene mutation profiles in primary diffuse large B cell lymphoma of central nervous system: next generation sequencing analyses. Int J Mol Sci 17. https:\/\/doi.org\/10.3390\/ijms17050683. E683 [pii]. ijms17050683 [pii]","DOI":"10.3390\/ijms17050683"},{"key":"20_CR93","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1007\/s00428-014-1622-6","volume":"465","author":"L Toffolatti","year":"2014","unstructured":"Toffolatti L et al (2014) MGMT promoter methylation and correlation with protein expression in primary central nervous system lymphoma. Virchows Arch 465:579\u2013586. https:\/\/doi.org\/10.1007\/s00428-014-1622-6","journal-title":"Virchows Arch"},{"key":"20_CR94","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1038\/leu.2014.264.leu2014264[pii]","volume":"29","author":"I Vater","year":"2015","unstructured":"Vater I et al (2015) The mutational pattern of primary lymphoma of the central nervous system determined by whole-exome sequencing. Leukemia 29:677\u2013685. https:\/\/doi.org\/10.1038\/leu.2014.264.leu2014264[pii]","journal-title":"Leukemia"},{"key":"20_CR95","doi-asserted-by":"publisher","unstructured":"Villano JL, Koshy M, Shaikh H, Dolecek TA, McCarthy BJ (2011) Age, gender, and racial differences in incidence and survival in primary CNS lymphoma. Br J Cancer 105:1414\u20131418. https:\/\/doi.org\/10.1038\/bjc.2011.357","DOI":"10.1038\/bjc.2011.357"},{"key":"20_CR96","doi-asserted-by":"publisher","unstructured":"Weller M, Martus P, Roth P, Thiel E, Korfel A (2012) Surgery for primary CNS lymphoma? Challenging a paradigm. Neuro Oncol 14:1481\u20131484. https:\/\/doi.org\/10.1093\/neuonc\/nos159. nos159 [pii]","DOI":"10.1093\/neuonc\/nos159"},{"key":"20_CR97","doi-asserted-by":"publisher","unstructured":"Yahalom J, Illidge T, Specht L, Hoppe RT, Li YX, Tsang R, Wirth A (2015) Modern radiation therapy for extranodal lymphomas: field and dose guidelines from the International lymphoma radiation oncology group. Int J Radiat Oncol Biol Phys 92:11\u201331. https:\/\/doi.org\/10.1016\/j.ijrobp.2015.01.009. S0360-3016(15)00050-4 [pii]","DOI":"10.1016\/j.ijrobp.2015.01.009"},{"key":"20_CR98","doi-asserted-by":"publisher","unstructured":"Yamashita K et al (2013) Differentiating primary CNS lymphoma from glioblastoma multiforme: assessment using arterial spin labeling, diffusion-weighted imaging, and (1)(8)F-fluorodeoxyglucose positron emission tomography. Neuroradiology 55:135\u2013143. https:\/\/doi.org\/10.1007\/s00234-012-1089-6","DOI":"10.1007\/s00234-012-1089-6"},{"key":"20_CR99","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1111\/j.1552-6569.2007.00231.x","volume":"18","author":"TT Zacharia","year":"2008","unstructured":"Zacharia TT, Law M, Naidich TP, Leeds NE (2008) Central nervous system lymphoma characterization by diffusion-weighted imaging and MR spectroscopy. J Neuroimaging 18:411\u2013417. https:\/\/doi.org\/10.1111\/j.1552-6569.2007.00231.x","journal-title":"J Neuroimaging"}],"container-title":["Advances in Experimental Medicine and Biology","Human Brain and Spinal Cord Tumors: From Bench to Bedside. Volume 2"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/978-3-031-23705-8_20","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,15]],"date-time":"2023-07-15T08:07:01Z","timestamp":1689408421000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/978-3-031-23705-8_20"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023]]},"ISBN":["9783031237041","9783031237058"],"references-count":99,"URL":"https:\/\/doi.org\/10.1007\/978-3-031-23705-8_20","relation":{},"ISSN":["0065-2598","2214-8019"],"issn-type":[{"value":"0065-2598","type":"print"},{"value":"2214-8019","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023]]},"assertion":[{"value":"16 July 2023","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}}]}}